AI clinical phenotyping turns a clinical definition — a disease, condition, complication, or eligibility criterion — into a computable phenotype: logic that identifies the patients who genuinely match that concept, using structured EHR data and unstructured notes together. It is the foundation beneath cohort identification for research, registry building, quality measurement, trial screening, and finding under-diagnosed or under-coded patients. A useful phenotype is not merely an algorithm that returns a list; it is a validated one, with performance measured against a clinical gold standard and documented well enough to be reproduced. The system identifies and ranks candidate patients with per-patient evidence; clinical and research experts define and validate the phenotype, and clinicians confirm any clinical action. The aim is cohorts that are accurate, reproducible, and defensible.
A phenotype is only as good as its validation
The temptation in computable phenotyping is to equate it with the model or the query, when the substance is whether the cohort that emerges actually corresponds to the clinical concept it claims to represent. That correspondence is not automatic. Diagnosis and billing codes, the most convenient signal, are well known to be incomplete and inconsistent proxies for clinical reality — present when a condition is absent, absent when it is present, applied for reimbursement rather than fidelity. The information that actually distinguishes a patient who has the condition from one who does not is distributed across laboratory values, medications, procedures, temporality, and the free text of clinical notes. A definition built on codes alone tends to over-capture, under-capture, or both, in ways that are invisible until someone checks.
A concrete illustration makes the point. Consider a phenotype for a condition that is frequently managed but inconsistently coded — one that clinicians document in their notes and treat pharmacologically, but do not always record as a discrete diagnosis. A code-only definition can miss a substantial fraction of true cases, those captured only narratively or inferable from laboratory values and medications, while simultaneously including patients who carry the code for a rule-out workup or for historical reasons they no longer meet. Combining the diagnostic code with corroborating laboratory thresholds, the medications typically used to treat the condition, and findings extracted from the notes produces a cohort that aligns far more closely with what a chart reviewer would call a true case. And it is the validation against that chart review which tells you, quantitatively rather than by assertion, how much closer.
Rigorous phenotyping treats this as the central problem. It combines multiple data modalities rather than trusting any single one, accounts for the temporal structure of a longitudinal record, and — critically — is validated against a clinical gold standard, typically chart review, with its performance reported in terms a reviewer can interrogate: positive predictive value, sensitivity, and specificity. Without that validation step, what you have is a list of uncertain provenance, not a phenotype you can stand behind in a study, a registry submission, or a quality program. The discipline of phenotyping is, in large part, the discipline of knowing how good your cohort is and being able to demonstrate it.
What AI clinical phenotyping delivers
A custom engagement generally delivers six things, mapped to how phenotyping is actually done.
Phenotype definition and translation. Working with your clinical and research experts, we translate a clinical concept into computable logic — inclusion and exclusion criteria expressed across codes, labs, medications, procedures, and timing — so the definition is explicit and reviewable rather than buried in a query.
Multi-modal data with NLP. Because so much phenotype-distinguishing signal exists only in narrative text, the approach combines structured data with information extracted from notes using NLP — findings, symptoms, severity, negation, and family-versus-patient context — rather than discarding the richest source of evidence.
Cohort identification and ranking. The phenotype is applied to the population to produce the matching cohort, with per-patient evidence and a confidence indication, so a reviewer can see why each patient was included rather than receiving an opaque list.
Validation against a gold standard. A sample is validated against chart review, performance is measured and reported as positive predictive value, sensitivity, and specificity, and the definition is iterated until it meets the bar the use case requires. This is the step that converts an algorithm into a defensible phenotype.
Portability and reproducibility. Phenotypes are documented, versioned, and — where appropriate — expressed against a common data model so they can be rerun reproducibly and ported across data sources or sites rather than living as a one-off script that no one can reconstruct later.
Integration into the downstream use. The resulting cohort feeds the workflow it was built for — a registry, a trial-screening pipeline, a quality measure, or clinician-facing identification — with human confirmation built in wherever the output touches a patient’s care.
A note on scope: phenotyping identifies who matches a clinical definition. Acting on an identified patient clinically requires clinician confirmation, and the ongoing care management of an identified panel is the work of a care coordination platform rather than of the phenotype itself. We keep these distinct so phenotyping stays focused on accurate, validated identification.
How it works with your data
Phenotyping runs on the clinical data you already hold, and the quality of the data foundation shapes everything above it. We connect to structured data and clinical notes through our FHIR API development and HL7 integration services, and where your environment uses a research data warehouse or a common data model such as OMOP, we build phenotypes to run against it so they are portable and reproducible. Handling the temporal and longitudinal structure of the record properly — what was true when, and in what order — is part of doing this correctly rather than an afterthought. This is one capability within our AI solutions for healthcare practice, and it is designed to work with your existing clinical data infrastructure.
Validation and rigor
Everything that makes a phenotype trustworthy is concentrated in how it is validated and documented. The validation is empirical: a reviewed sample compared against a clinical gold standard, with performance characterized honestly — including where the phenotype is weaker, not only where it is strong. The outputs are explainable at the patient level, so a clinician or informaticist can see the evidence behind each inclusion. The definition is documented and versioned so that a result can be reproduced and a change can be traced, which is what allows a phenotype to be cited in a study, submitted to a registry, or defended in a quality or regulatory context. We are also candid about a real limitation: a phenotype validated at one site, on one population and one documentation style, may perform differently elsewhere, so portability is something to be tested rather than assumed. Stating performance plainly, rather than attaching an invented accuracy figure, is part of the rigor.
Designing for the people who use cohorts
The users of phenotypes — clinical researchers, informaticists, quality teams — do not need a black box that emits a list; they need a defensible, reproducible definition they can scrutinize, validate, and adjust. The system is built for that working style: definitions are explicit and editable, validation is a first-class step rather than an optional extra, and iteration is supported because phenotyping is rarely right on the first pass. Domain experts remain the authors of the clinical concept and the arbiters of whether the cohort is correct; the software accelerates the construction, the multi-modal data work, and the validation, and keeps the human judgment where it belongs.
What to get right
A few principles separate phenotyping that holds up from phenotyping that quietly misleads. Do not rely on codes alone; combine structured data and text. Validate against a gold standard and report performance honestly, including the weaknesses. Document and version the definition so it is reproducible and citable. Treat portability as an empirical question, since performance can be site- and population-specific and bias can enter through the data. Require clinician confirmation before any output drives a clinical action. And establish governance — ownership of the definition, monitoring as data and coding practices change, and a defined process for revalidation — so the phenotype stays trustworthy over time.
How we build it
Productized, fixed-scope sprints, so the cost and timeline are known before you commit:
- Discovery Sprint — $45K, 4 weeks. Phenotype definition with your experts, data and common-data-model assessment, feasibility, and a validation plan ready for your committee.
- MVP Sprint — $95K, 8 weeks. A working, validated phenotype against a test environment, with multi-modal logic, NLP where needed, and gold-standard validation reported on real (de-identified) data.
- Pilot-Ready Sprint — $145K, 12 weeks. A production-ready, documented, and portable phenotyping pipeline integrated into the downstream use, with monitoring and the documentation your research, quality, or governance processes expect.
Ongoing support and revalidation run through our Care Packages ($8K / $20K / $50K per month). For a figure matched to your scope, use the cost calculator or begin with a Discovery Sprint.
What a build includes
Every engagement delivers more than a model. A phenotyping build typically includes the documented, versioned phenotype definition; the multi-modal logic and any NLP components; the cohort-identification pipeline with per-patient evidence; the gold-standard validation with reported performance metrics; portability against a common data model where appropriate; integration into the downstream registry, screening, quality, or identification workflow; a monitoring setup for data drift and revalidation; and the documentation your research and governance processes need. You own the source, the definitions, and the models — it is yours to operate, cite, and extend, not a license you rent. Scope, data, and acceptance criteria, including the validation bar, are fixed in writing during Discovery, so nothing is a moving target once the build begins.
Why build with Taction
We are an engineering and implementation partner, not a black-box vendor. You own the phenotypes, the code, and the models outright. The clinical concept and the judgment of whether a cohort is correct remain with your researchers and clinicians; the software accelerates the construction, the multi-modal data work, and the validation, and clinicians confirm any output that touches care. PHI is handled under a signed BAA, encrypted with AES-256 at rest and TLS 1.3 in transit, on ISO 27001-certified information-security practices. Across 13+ years and 785+ healthcare organizations, with deep experience in healthcare data and interoperability, we build phenotypes to be validated, reproducible, and defensible rather than merely plausible.
FAQ
What is AI clinical phenotyping?
It is the process of turning a clinical definition into a computable phenotype that identifies the patients who match it, using structured EHR data and unstructured notes together. It underpins cohort identification for research, registries, quality measurement, trial screening, and finding under-diagnosed patients. A phenotype is validated against a clinical gold standard and documented so it can be reproduced; experts define and validate it, and clinicians confirm any clinical action.
Why not just use diagnosis or billing codes?
Because codes are incomplete and inconsistent proxies for clinical reality — sometimes present when a condition is absent and absent when it is present. The distinguishing signal is spread across labs, medications, procedures, timing, and notes. Phenotyping that relies on codes alone tends to over- or under-capture in ways that are invisible without validation, which is why a rigorous approach combines modalities and adds NLP.
How do you validate a phenotype?
Empirically, against a clinical gold standard — typically chart review on a sample — with performance reported as positive predictive value, sensitivity, and specificity, and the definition iterated until it meets the bar the use case requires. Validation, with honest reporting of weaknesses, is what turns an algorithm into a defensible phenotype.
Does it use clinical notes, not just structured data?
Yes. Much of the signal that distinguishes patients exists only in narrative text, so the approach extracts findings, severity, negation, and patient-versus-family context from notes using NLP and combines that with structured data, rather than discarding the richest evidence source.
Are the phenotypes reproducible and portable across sites?
They are documented and versioned so results can be reproduced and changes traced, and where appropriate they are expressed against a common data model such as OMOP for portability. Portability is treated as something to be tested rather than assumed, because performance can be site- and population-specific.
Can it identify patients for clinical action?
It can support identification — for example, surfacing potentially under-diagnosed patients — but any output that touches a patient’s care requires clinician confirmation, and the ongoing care management of an identified panel is the role of a care coordination platform, not of the phenotype itself.
How long does it take to build?
Defining and validating a phenotype to MVP is an 8-week MVP Sprint; a production-ready, documented, portable pipeline integrated into the downstream use is a 12-week Pilot-Ready Sprint. A 4-week Discovery Sprint comes first to define the phenotype with your experts and set the validation plan.
Is patient data protected?
Yes. PHI is handled under a signed BAA, encrypted with AES-256 at rest and TLS 1.3 in transit, on ISO 27001-certified security practices, with de-identified data used during development wherever possible.
See what a validated phenotype would take for your cohort. Book a free consultation →
Reviewed by Taction Software’s healthcare engineering team. Taction is an engineering and implementation partner; clinical concepts, cohort validity judgments, and clinical decisions rest with your researchers and clinicians. ISO 27001-certified information security. PHI handled under a signed BAA.